133 related articles for article (PubMed ID: 23085464)
1. Effects of azacitidine on matrix metalloproteinase-9 in acute myeloid leukemia and myelodysplasia.
Bernal T; Moncada-Pazos A; Soria-Valles C; Gutiérrez-Fernández A
Exp Hematol; 2013 Feb; 41(2):172-9. PubMed ID: 23085464
[TBL] [Abstract][Full Text] [Related]
2. The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.
Almstedt M; Blagitko-Dorfs N; Duque-Afonso J; Karbach J; Pfeifer D; Jäger E; Lübbert M
Leuk Res; 2010 Jul; 34(7):899-905. PubMed ID: 20381863
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes.
Ries C; Loher F; Zang C; Ismair MG; Petrides PE
Clin Cancer Res; 1999 May; 5(5):1115-24. PubMed ID: 10353746
[TBL] [Abstract][Full Text] [Related]
4. 5-azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity.
Curik N; Burda P; Vargova K; Pospisil V; Belickova M; Vlckova P; Savvulidi F; Necas E; Hajkova H; Haskovec C; Cermak J; Krivjanska M; Trneny M; Laslo P; Jonasova A; Stopka T
Leukemia; 2012 Aug; 26(8):1804-11. PubMed ID: 22343522
[TBL] [Abstract][Full Text] [Related]
5. Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation.
Ørskov AD; Treppendahl MB; Skovbo A; Holm MS; Friis LS; Hokland M; Grønbæk K
Oncotarget; 2015 Apr; 6(11):9612-26. PubMed ID: 25823822
[TBL] [Abstract][Full Text] [Related]
6. Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML.
Ettou S; Audureau E; Humbrecht C; Benet B; Jammes H; Clozel T; Bardet V; Lacombe C; Dreyfus F; Mayeux P; Solary E; Fontenay M
Leukemia; 2012 Oct; 26(10):2297-9. PubMed ID: 22743624
[No Abstract] [Full Text] [Related]
7. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
Estey EH
Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301
[TBL] [Abstract][Full Text] [Related]
8. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
van der Helm LH; Alhan C; Wijermans PW; van Marwijk Kooy M; Schaafsma R; Biemond BJ; Beeker A; Hoogendoorn M; van Rees BP; de Weerdt O; Wegman J; Libourel WJ; Luykx-de Bakker SA; Minnema MC; Brouwer RE; Croon-de Boer F; Eefting M; Jie KS; van de Loosdrecht AA; Koedam J; Veeger NJ; Vellenga E; Huls G
Br J Haematol; 2011 Dec; 155(5):599-606. PubMed ID: 21981697
[TBL] [Abstract][Full Text] [Related]
9. Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia.
Claus R; Pfeifer D; Almstedt M; Zucknick M; Hackanson B; Plass C; Lübbert M
Leuk Res; 2013 Feb; 37(2):190-6. PubMed ID: 23158571
[TBL] [Abstract][Full Text] [Related]
10. [Effectiveness and safety of 5-azacitidine in three patients with myelodysplastic syndromes].
Garzás-Martín de Almagro MC; Gago Sánchez AI; Cuevas Asencio I; Reyes Malia M
Farm Hosp; 2010; 34(4):204-8. PubMed ID: 20185350
[TBL] [Abstract][Full Text] [Related]
11. Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes.
Travaglino E; Benatti C; Malcovati L; Della Porta MG; Gallì A; Bonetti E; Rosti V; Cazzola M; Invernizzi R
Eur J Haematol; 2008 Mar; 80(3):216-26. PubMed ID: 18081721
[TBL] [Abstract][Full Text] [Related]
12. Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes.
Follo MY; Finelli C; Mongiorgi S; Clissa C; Chiarini F; Ramazzotti G; Paolini S; Martinelli G; Martelli AM; Cocco L
Leukemia; 2011 Feb; 25(2):271-80. PubMed ID: 21109771
[TBL] [Abstract][Full Text] [Related]
13. Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia.
Thépot S; Lainey E; Cluzeau T; Sébert M; Leroy C; Adès L; Tailler M; Galluzzi L; Baran-Marszak F; Roudot H; Eclache V; Gardin C; de Botton S; Auberger P; Fenaux P; Kroemer G; Boehrer S
Cell Cycle; 2011 Jul; 10(14):2323-30. PubMed ID: 21654193
[TBL] [Abstract][Full Text] [Related]
14. Antiproliferative and antitumor effects of azacitidine against the human myelodysplastic syndrome cell line SKM-1.
Kimura S; Kuramoto K; Homan J; Naruoka H; Ego T; Nogawa M; Sugahara S; Naito H
Anticancer Res; 2012 Mar; 32(3):795-8. PubMed ID: 22399596
[TBL] [Abstract][Full Text] [Related]
15. Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms.
Greco M; D'Alò F; Scardocci A; Criscuolo M; Fabiani E; Guidi F; Di Ruscio A; Migliara G; Pagano L; Fianchi L; Chiusolo P; Hohaus S; Leone G; Voso MT
Blood Cells Mol Dis; 2010 Oct; 45(3):181-5. PubMed ID: 20655775
[TBL] [Abstract][Full Text] [Related]
16. Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia.
Lainey E; Wolfromm A; Marie N; Enot D; Scoazec M; Bouteloup C; Leroy C; Micol JB; De Botton S; Galluzzi L; Fenaux P; Kroemer G
Oncogene; 2013 Sep; 32(37):4331-42. PubMed ID: 23085751
[TBL] [Abstract][Full Text] [Related]
17. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes.
Silverman LR; Holland JF; Weinberg RS; Alter BP; Davis RB; Ellison RR; Demakos EP; Cornell CJ; Carey RW; Schiffer C
Leukemia; 1993 May; 7 Suppl 1():21-9. PubMed ID: 7683352
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment.
Follo MY; Russo D; Finelli C; Mongiorgi S; Clissa C; Filì C; Colombi C; Gobbi M; Manzoli L; Piazzi M; Martelli AM; Cocco L
Leukemia; 2012 May; 26(5):943-50. PubMed ID: 22033492
[TBL] [Abstract][Full Text] [Related]
19. Pilot study on combination of azacitidine and low-dose cytarabine for patients with refractory anemia with excess blast.
Moon JH; Lee SJ; Lee YJ; Kang BW; Chae YS; Kim JG; Suh JS; Sohn SK
Ann Hematol; 2012 Mar; 91(3):367-73. PubMed ID: 21947085
[TBL] [Abstract][Full Text] [Related]
20. Azacitidine versus decitabine in patients with refractory anemia with excess blast-Results of multicenter study.
Salim O; Toptas T; Avsar E; Yucel OK; Ozturk E; Ferhanoglu B; Geduk A; Mehtap O; Tombak A; Tiftik EN; Deveci B; Kurtoglu E; Kara O; Atagunduz IK; Tuglular TF; Undar L
Leuk Res; 2016 Jun; 45():82-9. PubMed ID: 27107658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
